Get the Stockscreener App
0.00
100.00%
-131.87
Intra Cellular Therapies Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
See More
Previous Close:
$131.87
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$14.05B
Revenue:
$612.78M
Net Income/Loss:
$-86.37M
P/E Ratio:
0.00
EPS:
-0.87
Net Cash Flow:
$-62.91M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$131.98
Intra Cellular Therapies Inc Stock (ITCI) Company Profile
Name
Intra Cellular Therapies Inc
Sector
Phone
(646) 440-9333
Address
135 ROUTE 202/206, BEDMINSTER, NY
Compare ITCI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ITCI
Intra Cellular Therapies Inc
|
0.00 | 14.05B | 612.78M | -86.37M | -62.91M | -0.87 |
|
HLN
Haleon Plc Adr
|
11.35 | 50.14B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
168.63 | 72.38B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.79 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 45.51B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.78 | 19.45B | 16.54B | -1.64B | 749.00M | -1.45 |
Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-25 | Downgrade | Mizuho | Outperform → Neutral |
| Jan-31-25 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-06-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-11-23 | Initiated | TD Cowen | Outperform |
| Apr-20-23 | Initiated | Morgan Stanley | Overweight |
| Aug-22-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-22-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Initiated | Goldman | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| Dec-15-20 | Initiated | BofA Securities | Buy |
| Dec-10-20 | Initiated | Goldman | Buy |
| Feb-20-20 | Initiated | Evercore ISI | Outperform |
| Jan-31-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-24-19 | Reiterated | Canaccord Genuity | Buy |
| Aug-12-19 | Initiated | Jefferies | Buy |
| Feb-26-18 | Initiated | JP Morgan | Overweight |
| Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Nov-08-17 | Upgrade | SunTrust | Hold → Buy |
| Sep-07-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-30-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Aug-24-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Aug-23-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| May-02-17 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| May-02-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| May-01-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-29-16 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-29-16 | Downgrade | SunTrust | Buy → Neutral |
View All
Intra Cellular Therapies Inc Stock (ITCI) Latest News
Intra-Cellular Therapies describes new PDE1 inhibitors - BioWorld MedTech
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Consensus Recommendation of “Hold” by Analysts - Defense World
Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by Analysts at StockNews.com - Defense World
(ITCI) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Purchased by Dimensional Fund Advisors LP - Defense World
Dealmaking Quarterly Statistics, Q1 2025 - insights.citeline.com
Press Release Distribution & PR Platform - ACCESS Newswire
Trend Tracker for (ITCI) - news.stocktradersdaily.com
Zynext Ventures Invests in Feldan Therapeutics to Drive Innovation in Intracellular Drug Delivery - Yahoo Finance
JNJ Tops Q1 Earnings, Ups '25 Sales View to Include Intra-Cellular Deal - TradingView
Johnson & Johnson Reports Q1 2025 Results - BioSpace
Intra-Cellular Therapies’ SWOT analysis: acquisition shifts landscape for psychiatric drug stock - Investing.com Canada
Intra-Cellular Therapies’ SWOT analysis: acquisition shifts landscape for psychiatric drug stock By Investing.com - Investing.com South Africa
Johnson & Johnson - drugdiscoverytrends.com
Johnson & Johnson Expects Lower Earnings Impact From Intra-Cellular Therapies Acquisition - MSN
J&J acquires Intra-Cellular Therapies in multi-billion-dollar deal - ROI-NJ
J&J to complete acquisition of Intra-Cellular Therapies - Medical Buyer
Johnson & Johnson buys Bedminster drugmaker for $14.6B - NJBIZ
JnJ closes Intra-Cellular Therapies acquisition - Medical Dialogues
JNJ forecasts 2025 profit dilution from Intra-Cellular deal, sets closing date - MSN
Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews - Benzinga
Intra-Cellular Therapies acquired by Johnson & Johnson for $14.6 billion - Investing.com South Africa
Intra-Cellular Therapies Completes Merger with Johnson & Johnson - TipRanks
Johnson & Johnson acquires Intra-Cellular Therapies By Investing.com - Investing.com South Africa
Stock Of The Day: Will Johnson & Johnson Rally? The Sell-Off May Have Ended - Benzinga
Johnson & Johnson Acquires Intra-Cellular Therapies - citybiz
Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership - BioSpace
Johnson & Johnson Completes Intra-Cellular Therapies Purchase - MarketScreener
JNJ Completes Acquisition Of Intra-Cellular Therapies - Nasdaq
Johnson & Johnson acquires Intra-Cellular Therapies - Investing.com
Johnson & Johnson completes Intra-Cellular Therapies acquisition, sees dilution - TipRanks
Johnson & Johnson (JNJ) Closes Intra-Cellular Therapies, Inc. (ITCI) Acquisition - StreetInsider
Johnson & Johnson Expands Its Horizon With Intra-Cellular Therapies Deal - Finimize
Johnson & Johnson Set To Complete Acquisition Of Intra-Cellular Therapies By April 2, 2025 - Nasdaq
Johnson & Johnson to finalize Intra-Cellular buyout By Investing.com - Investing.com Canada
Johnson & Johnson to finalize Intra-Cellular buyout - Investing.com
Johnson & Johnson Intra-Cellular acquisition to accelerate FY25 sales by 0.8% - TipRanks
Johnson & Johnson (JNJ) Sets April 2nd as Expected Closing Date for Intra-Cellular Acquisition - StreetInsider
Johnson & Johnson Announces Expected Closing Date for Intra-Cellular Acquisition - The Joplin Globe
Intra-cellular Therapeutics Surges to 322nd in Trading Volume Ranking with 3.36 Billion Shares Exchanged - AInvest
(ITCI) On The My Stocks Page - news.stocktradersdaily.com
Intra-cellular Therapies Surges to 340th in Daily Rankings with 2.46 Billion Turnover - AInvest
Intra-Cellular Therapies Stock Hits All-Time High of $131.79 By Investing.com - Investing.com South Africa
Intra-Cellular Therapies Shareholders Approve Johnson & Johnson Merger - Investing.com
Intra-Cellular Therapies Shareholders Approve Johnson & Johnson Merger By Investing.com - Investing.com Australia
Beam Therapeutics (BEAM) Down 21.4% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Intra-Cellular Therapies Stock Hits All-Time High of $131.79 - Investing.com
Intra-Cellular Therapies: These Are 5 Critical Challenges Threatening Its Expansion Plans! - Smartkarma
Intra-Cellular Therapies announces proxy statement supplement By Investing.com - Investing.com South Africa
Intra Cellular Therapies Inc Stock (ITCI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):